This would be in line with results of the REGARD trial, where there was no difference between IFN and GA in overall efficacy, but IFN showed a stronger effect on reduction of gadolinium-enhancing lesions, whereas GA had a stronger influence on reduction of brain atrophy.5 This evidence concerns the gene IFNA1 and Brain atrophy.